SQZ · Sqz Biotechnologies Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.13M | $178.0K | $2.87M | - | $3.45M | $3.21M | $2.87M | - | $4.75M | $5.98M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.50M | $12.73M | $12.98M | - | $19.63M | $18.76M | $17.01M | - | $20.52M | $12.04M |
| SG&A | $5.61M | $4.56M | $5.28M | - | $6.92M | $6.96M | $6.91M | - | $6.69M | $4.03M |
| Total Operating Expenses | $23.80M | $17.29M | $18.25M | - | $26.55M | $25.72M | $23.92M | - | $27.21M | $16.07M |
| D&A | $100.0K | $200.0K | $214.0K | - | $300.0K | $300.0K | $276.0K | - | $300.0K | $300.0K |
| Operating Income | ($23.80M) | ($17.11M) | ($18.25M) | - | ($23.10M) | ($22.50M) | ($21.05M) | - | ($22.46M) | ($10.09M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 | $0 |
| Net Income | ($23.64M) | ($16.77M) | ($17.69M) | - | ($22.64M) | ($22.24M) | ($21.04M) | - | ($22.45M) | ($19.07M) |
| EPS - Basic | ($0.80) | ($0.57) | ($0.60) | - | ($0.77) | ($0.68) | - | - | - | - |
| EPS - Diluted | ($0.80) | ($0.57) | ($0.75) | - | ($0.80) | ($0.78) | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.19M | $24.71M | $39.87M | $63.71M | $84.24M | $105.56M | $122.91M | $143.51M | $164.25M | $185.07M |
| Accounts Receivable | - | - | - | - | - | - | - | $3.00M | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.91M | $1.56M | $2.48M | $2.51M | $3.31M | $1.66M | $1.20M | $3.97M | $2.39M | $2.10M |
| Current Assets | $12.09M | $27.68M | $44.45M | $68.20M | $87.34M | $110.05M | $127.92M | $150.63M | $166.17M | $189.26M |
| Total Assets | $29.79M | $54.15M | $73.16M | $99.90M | $154.85M | $180.31M | $200.80M | $226.15M | $244.07M | $238.55M |
| Current Liabilities | $8.83M | $9.91M | $12.69M | $21.84M | $25.26M | $28.44M | $29.50M | $33.22M | $39.11M | $43.84M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $27.91M | $29.61M | $33.00M | $42.75M | $86.28M | $92.12M | $95.88M | $102.18M | $110.87M | $85.85M |
| Stockholders' Equity | $1.88M | $24.54M | $40.16M | $57.15M | $68.57M | $88.19M | $104.91M | $123.98M | $133.21M | $152.70M |
| Retained Earnings | ($333.07M) | ($309.43M) | ($292.66M) | ($274.97M) | ($261.43M) | ($238.78M) | ($216.55M) | ($195.51M) | ($183.69M) | ($161.24M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($23.77M) | - | - | - | ($20.43M) | - | - | - |
| Investing Cash Flow | - | - | ($65.0K) | - | - | - | ($194.0K) | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | $29.0K | - | - | - |
| CapEx | - | - | $65.0K | - | - | - | $228.0K | - | - | - |
| Free Cash Flow | - | - | ($23.84M) | - | - | - | ($20.66M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -760.4% | -9611.2% | -636.3% | - | -669.1% | -699.9% | -733.8% | - | -472.3% | -168.7% |
| EBITDA margin | -757.2% | -9498.9% | -628.8% | - | -660.4% | -690.6% | -724.2% | - | -466.0% | -163.6% |
| Net margin | -755.2% | -9421.3% | -616.5% | - | -655.9% | -691.6% | -733.3% | - | -472.1% | -318.9% |
| Free cash flow margin | - | - | -830.8% | - | - | - | -720.2% | - | - | - |
| FCF / Net income | - | - | 1.35 | - | - | - | 0.98 | - | - | - |
| R&D / Revenue | 335.6% | 7151.1% | 452.3% | - | 568.7% | 583.5% | 592.9% | - | 431.5% | 201.3% |
| SG&A / Revenue | 179.4% | 2560.1% | 184.0% | - | 200.4% | 216.4% | 240.9% | - | 140.7% | 67.4% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -79.4% | -31.0% | -24.2% | - | -14.6% | -12.3% | -10.5% | - | -9.2% | -8.0% |
| Return on equity | -1256.7% | -68.3% | -44.0% | - | -33.0% | -25.2% | -20.1% | - | -16.9% | -12.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.37 | 2.79 | 3.50 | 3.12 | 3.46 | 3.87 | 4.34 | 4.53 | 4.25 | 4.32 |
| Quick ratio | 1.37 | 2.79 | 3.50 | 3.12 | 3.46 | 3.87 | 4.34 | 4.53 | 4.25 | 4.32 |
| Cash ratio | 1.15 | 2.49 | 3.14 | 2.92 | 3.33 | 3.71 | 4.17 | 4.32 | 4.20 | 4.22 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 15.84 | 2.21 | 1.82 | 1.75 | 2.26 | 2.04 | 1.91 | 1.82 | 1.83 | 1.56 |
| Liabilities / Assets | 0.94 | 0.55 | 0.45 | 0.43 | 0.56 | 0.51 | 0.48 | 0.45 | 0.45 | 0.36 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.00 | 0.04 | - | 0.02 | 0.02 | 0.01 | - | 0.02 | 0.03 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.3% | -94.5% | 0.0% | - | -27.4% | -46.2% | -55.2% | - | -22.3% | - |
| Revenue CAGR (3y) | -20.0% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -3.0% | 24.0% | 13.3% | - | -2.9% | -123.1% | -92.2% | - | -168.2% | - |
| Net income growth (YoY) | -4.4% | 24.6% | 15.9% | - | -0.9% | -16.6% | -98.8% | - | -81.8% | - |
| EPS growth (YoY) | 0.0% | 26.9% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -15.4% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -97.3% | -72.2% | -61.7% | -53.9% | -48.5% | -42.2% | -38.0% | -2.5% | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing SQZ Biotechnologies Co against the 5 most active filers in the same SIC group.